The role and mechanism of autophagy in sorafenib targeted cancer therapy

被引：34

作者：

Yi Heqing ^{[1
]}

Long Bin ^{[1
]}

Ye Xuemei ^{[1
]}

Li Linfa ^{[1
]}

机构：

[1] Zhejiang Canc Hosp, Dept Nucl Med, 38 Guangji Rd, Hangzhou 310021, Zhejiang, Peoples R China

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2016年 / 100卷

关键词：

Sorafenib; Autophagy; Targeting kinase inhibitor; Acquired resistance; HEPATOCELLULAR-CARCINOMA CELLS; PROMOTES AUTOPHAGY; ACTIVATION; DEATH; INHIBITION; PATHWAY; BCL-2; MTOR;

D O I：

10.1016/j.critrevonc.2016.02.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeting kinase inhibitors (TKIs) are effective tools for treating advanced cancer. However, acquired resistance represents a roadblock in the use of TKIs, such as sorafenib, for cancer therapy. Understanding the acquisition of resistance to sorafenib will help doctors to cope with acquired resistance to TKIs in general and to develop personalized medicine strategies for cancer patients. Autophagy is a biological process that occurs in normal organisms. However, it is also a component of multiple disease processes, including cancer development and progression. However, the roles of autophagy in cancer and in response to cancer therapy are controversial. Id this review, we summarize the progress in autophagy and sorafenib resistance research, which is representative of acquired resistance to targeted cancer therapy. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：137 / 140

页数：4

共 26 条

[1] Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model [J].

Bard-Chapeau, Emilie A. ;

Nguyen, Anh-Tuan ;

Rust, Alistair G. ;

Sayadi, Ahmed ;

Lee, Philip ;

Chua, Belinda Q. ;

New, Lee-Sun ;

de Jong, Johann ;

Ward, Jerrold M. ;

Chin, Christopher K. Y. ;

Chew, Valerie ;

Han Chong Toh ;

Abastado, Jean-Pierre ;

Benoukraf, Touati ;

Soong, Richie ;

Bard, Frederic A. ;

Dupuy, Adam J. ;

Johnson, Randy L. ;

Radda, George K. ;

Chan, Eric Chun Yong ;

Wessels, Lodewyk F. A. ;

Adams, David J. ;

Jenkins, Nancy A. ;

Copeland, Neal G. .

NATURE GENETICS, 2014, 46 (01) :24-+

[2] Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR [J].

Caraglia, M. ;

Giuberti, G. ;

Marra, M. ;

Addeo, R. ;

Montella, L. ;

Murolo, M. ;

Sperlongano, P. ;

Vincenzi, B. ;

Naviglio, S. ;

Del Prete, S. ;

Abbruzzese, A. ;

Stiuso, P. .

CELL DEATH & DISEASE, 2011, 2 :e150-e150

[3] Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib [J].

Chen, D. ;

Zhao, P. ;

Li, S. -Q. ;

Xiao, W. -K. ;

Yin, X. -Y. ;

Peng, B. -G. ;

Liang, L. -J. .

EJSO, 2013, 39 (09) :974-980

[4] Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells [J].

Chen, Kuen-Feng ;

Chen, Hui-Ling ;

Tai, Wei-Tien ;

Feng, Wen-Chi ;

Hsu, Chih-Hung ;

Chen, Pei-Jer ;

Cheng, Ann-Lii .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 337 (01) :155-161

[5]

Dynamics of Cell Fate Decision Mediated by the Interplay of Autophagy and Apoptosis in Cancer Cells, 2015, ANTICANCER RES, V35, P4379

[6]

Fischer TD, 2014, WORLD J HEPATOL, V6, P752, DOI 10.4254/wjh.v6.i10.752

[7] MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1 [J].

Gao, C. ;

Peng, F. H. ;

Peng, L. K. .

NEOPLASMA, 2014, 61 (06) :680-689

[8] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J].

Gerlinger, Marco ;

Rowan, Andrew J. ;

Horswell, Stuart ;

Larkin, James ;

Endesfelder, David ;

Gronroos, Eva ;

Martinez, Pierre ;

Matthews, Nicholas ;

Stewart, Aengus ;

Tarpey, Patrick ;

Varela, Ignacio ;

Phillimore, Benjamin ;

Begum, Sharmin ;

McDonald, Neil Q. ;

Butler, Adam ;

Jones, David ;

Raine, Keiran ;

Latimer, Calli ;

Santos, Claudio R. ;

Nohadani, Mahrokh ;

Eklund, Aron C. ;

Spencer-Dene, Bradley ;

Clark, Graham ;

Pickering, Lisa ;

Stamp, Gordon ;

Gore, Martin ;

Szallasi, Zoltan ;

Downward, Julian ;

Futreal, P. Andrew ;

Swanton, Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) :883-892

[9] Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells [J].

Grimaldi, A. ;

Santini, D. ;

Zappavigna, S. ;

Lombardi, A. ;

Misso, G. ;

Boccellino, M. ;

Desiderio, V. ;

Vitiello, P. P. ;

Di Lorenzo, G. ;

Zoccoli, A. ;

Pantano, F. ;

Caraglia, M. .

CANCER BIOLOGY & THERAPY, 2015, 16 (04) :567-579

[10] Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression [J].

Kim, Hye Young ;

Jung, Hye Uk ;

Yoo, Seung Hee ;

Yoo, Ki Soo ;

Cheong, JaeHun ;

Park, Bong Soo ;

Yun, Il ;

Yoo, Young Hyun .

CANCER LETTERS, 2014, 355 (01) :61-69

← 1 2 3 →